PlantForm to meet with U.S. Army medical research personnel

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has invited PlantForm to give a presentation on the capabilities of our plant-based biopharmaceutical platform.

“Our process is well suited to produce a wide range of therapeutic drugs, including for treatment of Ebola and other biological threats,” said Don Stewart, PlantForm’s President and CEO. “Our plant system is unique in that we are able to remove any plant-specific glycosylation (protein sugar) patterns and produce drugs with fully mammalian glycosylation. This eliminates the risk that patients will have an unwanted immune system reaction to the drug, which is a very significant advantage.”

The presentation to USAMRIID and officials from other affiliated departments will take place in October.

PlantForm, PharmaPraxis establish joint venture

PlantForm and PharmaPraxis of Brazil have formed a joint venture – named PlantPraxis – to develop, manufacture and commercialize biosimilar and/or biobetter versions of six key biopharmaceuticals for the Brazilian market, using PlantForm’s low-cost manufacturing system.

PlantForm CEO Don Stewart and Chief Operating Officer David Cayea will be in Brazil Sept. 19-26 for discussions regarding the JV with officials from Bio-Manguinhos, Financiadora de Estudos e Projetos (FINEP, the Funding Authority for Studies and Projects) and the Brazilian Development Bank (BNDES).

The JV’s first drug target will be a biosimilar/biobetter version of the oncology drug Avastin® (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology. Read the news release.

Biosimilar Herceptin® (trastuzumab) update

Work is under way to scale-up manufacturing of PlantForm’s biosimilar trastuzumab drug candidate, and perform key physico-chemical and biological analyses, in preparation for Phase 1 human clinical trials in the next 12-18 months.

This phase of development, which will produce GMP (Good Manufacturing Practice) material for clinical trials, is supported by $2 million in equity financing from Atlantic Assets Trust. Roche’s Herceptin®, used to treat breast cancer, has global sales of $6 billion annually and faces patent expiry beginning this year.

PlantForm management is working to raise the funds necessary to advance into clinical trials through engagements with:
PlantForm has also engaged Bloom Burton & Co. for strategic advisory services to support the company’s growth and development.

Second U.S. patent

PlantForm has received a Notice of Allowance from the United States Patent and Trademark Office that a second patent will be granted for the company’s innovative, plant-produced antidote to cobra toxin.

Please share!

Join us online
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook.
Facebook page - PlantForm
September 2014

Rights offering

PlantForm is offering individual investors an opportunity to purchase shares at the current value of the company prior to the next significant raise.

The minimum subscription is $10,000 for current shareholders and $25,000 for new shareholders at $1.25 per share. The funds will be used to fund the further development of PlantForm’s biosimilar trastuzumab treatment for breast cancer and as general working capital. The closing date for the transaction will be Thursday, Sept. 18, 2014.

PlantForm will host a presentation for shareholders and prospective investors at the University of Guelph’s University Club, Sept. 15 from 7:30-9 p.m. Please RSVP to

Prairie Plant Systems contract

PlantForm has successfully completed a contract with Prairie Plant Systems Inc. (PPS), which involved PPS expressing an innovative biologic drug product using our plant-based system. Prairie Plant Systems is a privately held plant biotech company based in Saskatoon, Canada.
In the News

Plant-based biopharma manufacturing burst into the global media spotlight in August with the news that Mapp Biopharmaceutical’s plant-made antibody drug was used to successfully treat two American health workers infected with Ebola virus.

PlantForm’s system was featured in Plant-made drugs could be the future, Al Jazeera America (Aug. 22) and 'Plantibodies' drugs advance as big pharma stands aside, Reuters (Aug. 17).

Other recent media coverage:

CBC’s The Exchange with Amanda Lang (Aug. 13)
GaBI online (Aug. 22)
(July 23)
The Biosimilarz Blog! (July 8)
(July 2)
YongeStreet (June 11)

Sept 15 | PlantForm will host a presentation for shareholders and potential investors at the University of Guelph’s University Club, from 7:30-9 p.m.
Please RSVP to

Sept. 17 | We present at Life Science Nation’s Redefining Early Stage Investments conference in Boston, MA

Sept. 18 | Our AGM takes place at 11 a.m. at 120 Research Lane, Suite 200 in Guelph. Shareholders please email your intent to attend to

Nov. 3-5 | We’ll advance partnering discussions at the BIO-Europe conference in Frankfurt, Germany.

PlantForm is a Canadian company focused on providing
 therapeutic antibody drugs that fight cancer and other critical illnesses.
Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
For more information, contact:
Don Stewart
President & CEO